Total Voting Rights (1759C)

TIDMHIK

RNS Number : 1759C

Hikma Pharmaceuticals Plc

02 March 2011

Hikma Pharmaceuticals PLC - Voting Rights and Capital

LONDON, 2 March 2011 Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 28 February 2011 its capital consists of 193,560,989 ordinary shares with voting rights. There are no shares held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and Transparency Rules.

- ENDS -

Enquiries:

 
 Hikma Pharmaceuticals PLC 
 Henry Knowles 
  Company Secretary           +44 20 7399 2760

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2009, Hikma achieved revenues of $637 million and profit attributable to shareholders of $78 million. For news and other information, please visit www.hikma.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVREANDAESSFEEF

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024